FDA Calendar for Amylin Pharmaceuticals, Inc. (AMLN)

| Register (free)
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. As of December 31, 2008, the Company was marketing two medicines to treat diabetes: BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection. In addition to its marketed products, the Company is working with Eli Lilly and Company (Lilly) and Alkermes, Inc. (Alkermes) to develop exenatide once weekly. The Company maintains a discovery research program focused on peptide and protein therapeutics.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
BYETTA (EXENATIDE) Diabetes Pending DecisionPhase 3
Bydureon Diabetes Pending DecisionPhase 3


Events

No future events listed at this time, please check back later.
2 past event(s) found. Click here to view them.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

AMLN

$17.10
-0.66 -3.72%
2/3/2012 4:00:00 PM

Sponsors

Other Links